CAPSTANTX
LIVE

Serial Number

98850043

Owner

CAPSTAN THERAPEUTICS, INC.

Attorney

Joi A. White

Filing Date

Nov 12, 2024

Add to watchlist:

No watchlists yet
View on USPTO

CAPSTANTX Trademark

Serial Number: 98850043

CAPSTANTX is a trademark filed by CAPSTAN THERAPEUTICS, INC. on November 12, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

CAPSTAN THERAPEUTICS, INC. (4 trademarks)

9880 Campus Point Drive, Suite 220
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

November 12, 2024

Registration Date

Not Registered

Goods & Services

Pharmaceuticals; pharmaceutical preparations; pharmaceutical substances; therapeutics; therapeutic agents; biopharmaceuticals; medicines; drugs; vaccines; in vivo cell therapies; cells for medical or clinical use; stem cells for medical purposes; cells for medical use; genetically engineered cells; systems to express therapeutic proteins in vivo; gene therapy products; gene therapy preparations; gene therapy products, namely, genetically engineered cells for transplant purposes; in vivo nucleic acid, DNA, RNA, and mRNA technologies; targeted in vivo RNA technologies; lipid nanoparticles for medicinal use; binding moiety decorated lipid nanoparticles for medicinal use; lipid nanoparticles for durable cell reprogramming or cell engineering; binding moiety decorated lipid nanoparticles for durable cell reprogramming or cell engineering; targeted lipid nanoparticles for medicinal use; targeted lipid nanoparticles for durable cell reprogramming or cell engineering; targeted lipid nanoparticles for transient cell reprogramming or cell engineering; cell engineering platforms; cell engineering platforms for treatment of human diseases, disorders and conditions; technology platforms for developing and engineering therapeutic cells; in vivo cell engineering platforms; transient in vivo cell engineering platforms for durable gene therapy; technology platforms for transfection, namely, binding moiety decorated lipid nanoparticles for genetic engineering; reagents for transfection; reagents for transfection in vivo; reagents for transfection, namely, binding moiety decorated lipid nanoparticles; technology platforms for delivery of a payload by binding moiety decorated lipid nanoparticles including antibody decorated lipid nanoparticles; technology platforms for delivery of a nucleic acid payload; technology platforms for delivery of a negatively charged payload; biologics delivery systems; biologics delivery platforms; reagents for delivery of a payload by binding moiety decorated lipid nanoparticles including antibody decorated lipid nanoparticles; cell engineering platforms consisting of reagents, lipid nanoparticles, cell receptors, proteins, recombinant protein binders, mRNA, and antibodies or antigen binding portions thereof; biological technology platforms consisting of reagents, lipid nanoparticles, cell receptors, proteins, recombinant protein binders, nucleic acid, DNA, RNA, mRNA, and antibodies or antigen binding portions thereof, for the treatment and prevention of treatment of human diseases, disorders and conditions; chemical reagents for medical uses; clinical medical reagents; reagents for medical use; biological reagents for medical use; binding moiety decorated lipid nanoparticles

Filing History

REPORT UNRESPONSIVE AMENDMENT - COMPLETED
Dec 5, 2025 NAUD
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 7, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 7, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 7, 2025 TROA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Nov 6, 2025 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 6, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 6, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 6, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 6, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 6, 2025 COAR
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Aug 20, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Aug 20, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 22, 2025 GNRN
NON-FINAL ACTION E-MAILED
May 22, 2025 GNRT
NON-FINAL ACTION WRITTEN
May 22, 2025 CNRT
ASSIGNED TO EXAMINER
May 8, 2025 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
May 6, 2025 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 6, 2025 NWOS
NEW APPLICATION ENTERED
Nov 12, 2024 NWAP